Article
RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.
Molecular cancer research : MCR - 2 Jan 2026
Baars Beau, Orive-Ramos Ana, Emmett Matthew J, Gaire Bijaya, Desaunay Mathieu, Kou Ziyue, Li Guangyan, Adamopoulos Christos, Aaronson Stuart A, Wang Shaomeng, Sellers William R, Martin Tiphaine, Gavathiotis Evripidis, Poulikakos Poulikos I
Abstract excerpt
A high therapeutic index, defined as potent inhibition of oncogenic signaling in tumor cells with minimal effects on normal cells, is critical for effective cancer therapies. Recent advances have introduced diverse RAS-targeting inhibitors, including mutant-specific inhibitors such as KRAS G12C and KRAS G12D, as well as paralog- and state-selective inhibitors. Non-mutant-specific RAS inhibition can be achieved...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.